Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Blebbistatin** is a small molecule myosin II inhibitor that selectively blocks non-muscle myosin II ATPase activity (IC50 ~0.5-5 μM), with potency against cardiac, skeletal, and smooth muscle myosins but sparing myosin I, V, and X. It binds between the nucleotide pocket and actin-binding cleft in an actin-detached conformation, inhibiting actin-myosin interaction, cell migration, cytokinesis, bleb formation, and muscle contraction. Widely used in research for cardiovascular studies, cell biology, and optical heart mapping, though limited by photo-instability under blue light, fluorescence interference, and cytotoxicity during long-term exposure; derivatives like para-nitroblebbistatin address these issues.[1][4][7][8][16]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on blebbistatin.